Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich

Simply Wall St.08-17

Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period. See ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660096101?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-08-17 09:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660096101","market":"sg","top_or_hot":-1,"title":"Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich","media":"Simply Wall St.","content":"<div>\n<p>Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period. See ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-17 09:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period. See ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati","article_id":"2660096101","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660096101","pubTimestamp":1786929928,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period.\nSee our latest analysis for Edgewise Therapeutics.\nDespite the wider loss, Edgewise Therapeutics shares have shown strong momentum, with a 30 day share price return of 11.09% and an 85.98% year to date share price return. The 1 year total shareholder return of 212.16% and 3 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Edgewise Therapeutics (EWTX) 报告称，估值仍然很高，但出现了更广泛的损失","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1.5},"content_text":"Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period. See our latest analysis for Edgewise Therapeutics. Despite the wider loss, Edgewise Therapeutics shares have shown strong momentum, with a 30 day share price return of 11.09% and an 85.98% year to date share price return. The 1 year total shareholder return of 212.16% and 3 year total shareholder return above 5x reflect how investors have reacted over a longer period. If you are weighing what this kind of move might mean for other opportunities in healthcare, it could be a useful moment to scan 42 healthcare AI stocks. Edgewise Therapeutics shares have rerated sharply, while the latest analyst target still sits above the current price. The spread between that reference point and today’s valuation raises a simple question: Is the stock already fair, or not yet there? AdvertisementPreferred Price-to-Book Multiple of 10.7x: Is It Justified For Edgewise Therapeutics? With Edgewise Therapeutics last closing at $44.17 and trading on a P/B ratio of 10.7x, investors are effectively paying a high premium to the company’s current book value. That stands in contrast to the broader US Pharmaceuticals sector, where the average P/B sits at 2.5x. The P/B multiple compares a company’s market value to its net assets on the balance sheet. For a business like Edgewise Therapeutics that is still in the development stage and currently unprofitable, a higher P/B often reflects expectations around the future value of its pipeline rather than its present financials. In this case, the market is assigning a substantially richer valuation than the sector average. The 10.7x P/B suggests investors are pricing in strong potential from assets such as sevasemten and the broader precision medicine pipeline, even though Edgewise Therapeutics reports no meaningful revenue and continues to record losses. Compared with the US Pharmaceuticals industry average of 2.5x, the stock trades on more than four times the sector level, which signals that expectations embedded in the price are materially higher than those for many peers. On a peer comparison, however, Edgewise Therapeutics screens differently. Its 10.7x P/B is below the peer group average of 47.2x. Within that smaller set of companies with similar characteristics, it does not sit at the extreme end of valuations. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book ratio of 10.7x (OVERVALUED) However, Edgewise Therapeutics still carries clear risks, including its current losses of $197.222 million and its reliance on clinical trial progress for pipeline assets. Find out about the key risks to this Edgewise Therapeutics narrative. Next Steps With sentiment on Edgewise Therapeutics so divided between its potential and its risks, it makes sense to move quickly and review the full picture yourself. Take a closer look at the balance of risk and reward by checking the 1 key reward and 2 important warning signs Looking for more investment ideas beyond Edgewise Therapeutics? Do not stop with Edgewise Therapeutics. Use this momentum to scan other stocks so you are not missing opportunities that better fit your goals and risk comfort.  Target resilient companies by checking the 80 resilient stocks with low risk scores that may help you keep your portfolio steadier when markets move. Hunt for potential bargains by reviewing the 52 high quality undervalued stocks that combine quality fundamentals with pricing that might still be attractive. Strengthen your income plan by using the 10 dividend fortresses that could help you focus on higher yielding stocks with more robust payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Edgewise Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660096101","isCrawlerRequest":true}